A biosimilar drug to the tumor necrosis factor inhibitor adalimumab, marketed as Idacio (adalimumab-aacf), has been approved by the Food and Drug Administration for use in the United States, according to a press release from manufacturer Fresenius Kabi.
Idacio is a citrate-free, low-concentration formulation of adalimumab and is now approved for use for all but three of the indications that currently apply to the reference adalimumab product (Humira): rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis in adults, ankylosing spondylitis, Crohn's disease in adults and children aged 6 years or older, ulcerative colitis in adults, and plaque psoriasis in adults. It does not apply to Humira's indications for hidradenitis suppurativa, uveitis, or ulcerative colitis in pediatric patients aged 5 years and older.
Idacio is the eighth adalimumab biosimilar to be approved in the United States. Its approval was based on evidence of a similar profile of pharmacokinetics, safety, efficacy, and immunogenicity to Humira.
Idacio was first launched in 2019 and has been marketed in more than 37 countries worldwide, according to Fresenius Kabi. The US launch is scheduled for July, and Idacio will be available as a self-administered pre-filled syringe or pre-filled pen.
For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn
Credit:
Lead image: Fresenius Kabi
Medscape Medical News © 2022 WebMD, LLC
Send news tips to news@medscape.net.
Cite this: FDA Approves Idacio as Eighth Adalimumab Biosimilar in US - Medscape - Dec 15, 2022.
Comments